ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
Data Readoutpositive177Lu-edotreotideEverolimusPositive
AI Analysis
Summary
ITM announced positive Phase 3 COMPETE trial results published in The Lancet showing 177Lu-edotreotide significantly improved progression-free survival versus everolimus in advanced GEP-NETs patients. The trial randomized 309 patients across 49 global sites and provides first high-level evidence directly comparing PRRT with systemic standard-of-care therapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Patients
309
Outcome Details
177Lu-edotreotide significantly improved progression-free survival compared to everolimus in patients with Grade 1 or Grade 2 SSTR-positive GEP-NETs
Importance:8/10
Sentiment:
0.85
radiopharmaceuticalneuroendocrine tumorspeptide receptor radionuclide therapyPRRTPhase 3 resultspublicationThe Lancet
Read the original article
Published by GlobeNewswire Clinical Studies on July 7, 2026 9:00 AM